A five arm natural history study of nasal vestibulitis

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 8; pp. 9650 - 9654
• Main Authors: Cathcart‐Rake, Elizabeth J., Zahrieh, David, Smith, Deanne, Young, Susan, McCue, Shaylene, O'Connor, Amanda, Thomé, Stephan, Lacouture, Mario, Register, Terra, Piens, Jill, Friday, Bret B., Loprinzi, Charles L.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2023; John Wiley and Sons Inc; Wiley
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Asthma; Bevacizumab; Bevacizumab - adverse effects; Breast cancer; Breast Neoplasms - drug therapy; Brief Communication; Cancer therapies; Chemotherapy; chemotherapy side effects; Docetaxel; Female; Growth factors; Humans; nasal vestibulitis; Paclitaxel; Patients; Prospective Studies; Questionnaires; symptom management; Taxanes; symptom management; nasal vestibulitis; chemotherapy side effects
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.5887

Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non‐bevacizumab) chemotherapy regimens were invited to participate in this prospective study. Patients reported nasal symptoms prior to each dose of chemotherapy. Results The percentage of patients (95% CI) who reported nasal symptoms was the same for patients who received bevacizumab or nab‐paclitaxel, 82.6% (61.2%, 95.1%). There were no significant differences among the proportions of patients experiencing nasal symptoms within the paclitaxel, nab‐paclitaxel, and bevacizumab cohorts. Patients in the nab‐paclitaxel cohort were more likely to experience symptoms than those in the non‐taxane non‐bevacizumab cohort or docetaxel cohort (p = 0.001, p = 0.001). Patients in the bevacizumab cohort were more likely to experience nasal symptoms than those in the non‐taxane non‐bevacizumab cohort (p = 0.03). Conclusion Nasal vestibulitis symptoms are common in patients receiving chemotherapy, especially those receiving paclitaxel, docetaxel, and bevacizumab. Further investigations into treatments of this symptom complex are warranted. Nasal vestibulitis symptoms are common in patients receiving chemotherapy, especially thosereceiving paclitaxel, docetaxel, and bevacizumab. Further investigations into treatments of thissymptom complex are warranted.